Physician profile
Maroun E Hayek
NPI 1922072891
$6,525.64
in general payments reported to CMS, 2019-2025
40 companies · $697 in 2025
The $697 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $53.05 · 2021: $54.64 · 2022: $851 · 2023: $4,250 · 2024: $492 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,818 · Food and Beverage: $1,549 · Travel and Lodging: $1,057 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,818.00 |
| Food and Beverage | $1,548.89 |
| Travel and Lodging | $1,056.64 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $3,981.07 | 2023-2025 | Monjuvi |
| Beigene USA, INC. | $525.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $324.51 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $203.78 | 2020-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Gilead Sciences, INC. | $155.96 | 2021-2025 | Trodelvy |
| Puma Biotechnology, INC. | $113.45 | 2019-2025 | |
| Amgen INC. | $87.88 | 2019-2023 | Lumakras |
| Astellas Pharma US INC | $85.67 | 2023-2025 | Xtandi, Vyloy, Xospata |
| Daiichi Sankyo INC. | $81.49 | 2024-2025 | Enhertu, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $74.37 | 2022-2025 | Opdualag, Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $68.40 | 2023-2025 | Ninlaro, Iclusig |
| Pfizer INC. | $63.16 | 2019-2025 | |
| Celgene Corporation | $55.53 | 2023-2025 | Reblozyl |
| Karyopharm Therapeutics INC. | $53.92 | 2020-2025 | Xpovio |
| Astrazeneca Pharmaceuticals LP | $49.38 | 2024-2025 | Enhertu, Imfinzi |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $43.44 | 2022 | |
| Emd Serono, INC. | $38.13 | 2022-2024 | |
| Genzyme Corporation | $36.60 | 2022 | |
| Janssen Pharmaceuticals, INC | $36.33 | 2021-2023 | Xarelto |
| Sobi, INC | $35.63 | 2023-2024 | |
| Stemline Therapeutics INC. | $33.80 | 2023-2024 | Orserdu |
| Glaxosmithkline, LLC. | $32.90 | 2023-2024 | Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $27.26 | 2020-2025 | |
| Eisai INC. | $27.02 | 2019 | |
| Mirati Therapeutics, INC. | $26.13 | 2023 | Krazati |
| Pharmacyclics LLC, An Abbvie Company | $26.03 | 2022-2023 | Imbruvica |
| Myriad Genetic Laboratories, INC. | $25.59 | 2025 | Myrisk |
| Genmab U.S., INC. | $21.16 | 2024 | Epkinly |
| Lilly USA, LLC | $20.98 | 2025 | Verzenio, Jaypirca |
| Abbvie INC. | $19.34 | 2024 | |
| Aveo Pharmaceuticals, INC. | $17.85 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $17.78 | 2025 | Libtayo |
| Exelixis INC. | $16.53 | 2022 | |
| Legend Biotech USA INC. | $15.99 | 2025 | Carvykti |
| Janssen Biotech, INC. | $15.58 | 2025 | Talvey |
| Novocure INC. | $14.55 | 2025 | Optune Lua (Novottf-200t) |
| Clovis Oncology, INC. | $14.13 | 2020 | |
| Caris Mpi, INC. | $13.99 | 2025 | Mi Cancer Seek |
| Beone Medicines USA, INC. | $13.83 | 2025 | Brukinsa |
| Epizyme, INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maroun Hayek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.